Recent advances in antibiotic regimens for the treatment of obstetric-gynecologic infections

Clinical Therapeutics

Volumn 18, Issue 2, 1996, Pages 214-227

  Zambrano, David ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; AZLOCILLIN; AZTREONAM; CEFOPERAZONE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLINDAMYCIN; DOXYCYCLINE; GENTAMICIN; IMIPENEM; METRONIDAZOLE; MONOBACTAM; PENICILLIN DERIVATIVE; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTERIOLOGY; CHLAMYDIA TRACHOMATIS; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; FEMALE; GRAM NEGATIVE BACTERIUM; GYNECOLOGIC INFECTION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; OBSTETRICS; ORAL DRUG ADMINISTRATION; PELVIC INFLAMMATORY DISEASE; PRACTICE GUIDELINE; PSEUDOMEMBRANOUS COLITIS; REVIEW; UTERINE CERVIX; VAGINA;

EID: 0029980072     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80002-6     Document Type: Article

References (72)

1. Sweet RL, Gibbs RS. Antimicrobial agents. In: Infectious Diseases of the Female Genital Tract. 2nd ed. Baltimore: Williams & Wilkins; 1990:314-349.
2. Walker CK, Kahn JG, Washington AE, et al. Pelvic inflammatory disease: Meta-analysis of antimicrobial regimen efficacy. J Infect Dis. 1993;168:969-978.
3. McCormack WM. Pelvic inflammatory disease. NEJM. 1994;330:115-119.
4. Hill GB, Eschenbach DA, Holmes KK. Bacteriology of the vagina. Scand J Urol Nephrol. 1984;86(Suppl):23-39.
5. Speigel CA, Amsel R, Eschenbach DA. Anaerobic bacteria in nonspecific vaginitis. NEJM. 1980;303:601-604.
6. Hillier SL, Krohn MA, Watts DH, et al. Microbiologic efficacy of intravaginal clindamycin cream for the treatment of bacterial vaginosis. Obstet Gynecol. 1990;76:407-413.
7. Watts DH, Krohn MA, Hillier SL, Eschenbach DA. Bacterial vaginosis as a risk factor for postcesarean endometritis. Obstet Gynecol. 1990;75:52-57.
8. Silver HM, Sperling RS, St. Clair PJ, Gibbs RS. Evidence relating bacterial vaginosis to amniotic fluid infection. Am J Obstet Gynecol. 1989;161:808-812.
9. Hillier SL, Martius J, Krohn MA, et al. A case-control study of chorioamnion infection and histologic chorioamnionitis in prematurity. NEJM. 1988;319:972-978.
10. Larsson D-G, Bergman B, Forsum U, et al. Mobiluncus and clue cells as predictors of PID after first-trimester abortion. Acta Obstet Gynecol Scand. 1989;68:217-221.
11. Soper DE, Bump RC, Hurt WG. Bacterial vaginosis and trichomoniasis vaginitis are risk factors for cuff cellulitis after abdominal hysterectomy. Am J Obstet Gynecol. 1990;163:1016-1023.
12. Eschenbach DA, Buchanan TM, Pollock HM. Polymicrobial etiology of acute pelvic inflammatory disease. NEJM. 1975; 293:166-171.
13. Sutter VL. Frequency of occurrence and antimicrobial susceptibility of bacterial isolates from the intestinal and female genital tracts. Rev Infect Dis. 1983;5 (Suppl 1):S84-S89.
14. Thompson SE, Hager WD, Wong K-H. The microbiology and therapy of acute pelvic inflammatory disease in hospitalized patients. Am J Obstet Gynecol. 1980; 136:179-183.
15. Brunham RC, Binns B, Guijon F. Etiology and outcome of acute pelvic inflammatory disease. J Infect Dis. 1988;158: 510-517.
16. Hoyme VR, Kiviat N, Eschenbach DA. Microbiology and treatment of late post-partum endometritis. Obstet Gynecol. 1986;68:226-232.
17. Arredondo García JL, Figueroa Damian R, Ortiz Ibarra FJ, Sosa Gonzalez IE. Endometritis etiology: Diagnosis and treatment experience at the Instituto Nacional de Perinatología. Curr Ther Res. 1993; 54:529-539.
18. Berenson AB, Hammill HA, Martens MG, Faro S. Bacteriologic findings of post-cesarean endometritis in adolescents. Obstet Gynecol. 1990;75:627-629.
19. Ledger WJ, Norman M, Gee CL. Bacteremia on an obstetric-gynecologic service. Am J Obstet Gynecol. 1975;121: 205-210.
20. Monif GRG, Baer H. Polymicrobial bacteremia in obstetric patients. Obstet Gynecol. 1976;48:167-172.
21. Sweet RL, Yonekura ML, Hill G. Appropriate use of antibiotics in serious obstetric and gynecologic infections. Am J Obstet Gynecol. 1983;146:719-739.
22. Sweet RL, Schachter J, Robbie MO. Failure of beta-lactam antibiotics to eradicate Chlamydia trachomatis in the endometrium despite apparent clinical cure of acute salpingitis. JAMA. 1983;250: 2641-2645.
23. Gorbach SL. Antibiotic treatment of anaerobic infections. Clin Infect Dis. 1994;18(Suppl 4):S305-S310.
24. Centers for Disease Control. CDC recommended treatment schedules, 1974. Morb Mort Wkly Rep. 1974;23:431-445.
25. Thompson SE, Brooks C, Eschenbach DA, et al. High failure rates in outpatient treatment of salpingitis with either tetracycline alone or penicillin/ampicillin combination. Am J Obstet Gynecol. 1985;152: 635-641.
26. Chow AW, Marshall JR, Guze LB. A double-blind comparison of clindamycin with penicillin plus chloramphenicol in treatment of septic abortion. J Infect Dis. 1977;135(Suppl):S35-S39.
27. Ridgway GL, Mumtaz G, Gabriel FG. The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro. Eur J Clin Microbiol. 1984;3:344-346.
28. Barry AL, Jones RN, Thornsberry C, et al. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin and nalidixic acid. Antimicrob Agents Chemother. 1984;25:633-637.
29. Chin NX, Neu HC. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1984; 25:319-325.
30. Goldstein EJC, Citron DM. Susceptibility of anaerobic bacteria isolated from intraabdominal infections to ofloxacin and interaction of ofloxacin with metronidazole. Antimicrob Agents Chemother. 1991;35: 2447-2449.
31. Watt B, Brown FV. Is ciprofloxacin active against clinically important anaerobes? J Antimicrob Chemother. 1986;17:605-613.
32. Apuzzio JJ, Stankiewicz R, Jain S, et al. Comparison of parenteral ciprofloxacin with clindamycin-gentamicin in the treatment of pelvic infection. Am J Med. 1989;87(Suppl 5A):148S-151S.
33. Thadepalli H, Mathai D, Scotti R. Ciprofloxacin monotherapy for acute pelvic infections: A comparison with clindamycin plus gentamicin. Obstet Gynecol. 1991; 78:696-700.
34. Heinonen PK, Teisala K, Aine R. Brief report: Intravenous and oral ciprofloxacin in the treatment of proven pelvic inflammatory disease. A comparison of ciprofloxacin with doxycycline plus metronidazole. Am J Med. 1989;87(Suppl 5A): 152S-156S.
35. Crombleholme WR, Schachter J, Ohm-Smith MJ, et al. Efficacy of single-agent therapy for treatment of acute pelvic inflammatory disease with ciprofloxacin. Am J Med. 1989;87(Suppl 5A):142S-145S.
36. Maccato ML, Faro S, Martens MG, Hammill HA. Ciprofloxacin versus gentamicin/clindamycin for postpartum endometritis. J Reprod Med Obstet Gynecol. 1991;36:857-861.
37. Hillier SL, Eschenbach DA, Zambrano D. Obstetric gynecologic infections. In: Zambrano D, ed. Clindamycin in the Treatment of Human Infections. 2nd ed. Kalamazoo, Mich: Pharmacia & Upjohn, Inc. In press.
38. O'Keefe JP, Venezio FR, Divincenzo CA, Shatter KL. Activity of newer beta-lactam agents against clinical isolates of Bacteroides fragilis and other bacteroides species. Antimicrob Agents Chemother. 1987;31:2002-2006.
39. Tally FP, Cuchural GJ, Jacobus NV. Susceptibility of the Bacteroides fragilis group in the United States in 1981. Antimicrob Agents Chemother. 1983;23: 536-540.
40. Jones RN, Barry AL, Aldrige KE. Comparative antimicrobial activity of aminothiazolyl methoxyimino cephalosporins against anaerobic bacteria, including cefoxitin-resistant isolates. Diagn Microbiol Infect Dis. 1987;8:157-162.
41. Dodson MG. Clindamycin, anaerobes and acute pelvic inflammatory disease. Rev Contemp Pharmacother. 1992;3:269-274.
42. Rasmussen BA, Bush K, Tally FP. Antimicrobial resistance in Bacteroides. Clin Infect Dis. 1993;16(Suppl 1):S390-S400.
43. Ingham HR, Eaton S, Venables CW. Bacteroides fragilis resistant to metronidazole after long-term therapy. Lancet. 1978; 1:214.
44. Sprott MS, Ingham HR, Hickman JE. Metronidazole-resistant anaerobes. Lancet. 1983;1:1220.
45. Jones RN. Review of the in vitro spectrum of activity of imipenem. Am J Med. 1985;78:22-32.
46. Chambers HF, Neu HC. Carbapenems. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. IV ed. New York: Churchill Livingstone; 1995:264-272.
47. Steigbigel NH. Macrolides and clindamycin. In: Mandell GL, Bennett JE, Dolin R. eds. Principles and Practice of Infectious Diseases. IV ed. New York: Churchill Livingstone; 1995:341-346.
48. Centers for Disease Control. 1993. Sexually transmitted diseases treatment guidelines. MMWR. 1993;42(RR-14):75-81.
49. Walters MD, Gibbs RS. A randomized comparison of gentamicin-clindamycin and cefoxitin-doxycycline in the treatment of acute pelvic inflammatory disease. Obstet Gynecol. 1988;72:7-12.
50. Soper DE, Despres B. A comparison of two antibiotic regimens for treatment of pelvic inflammatory disease. Obstet Gynecol. 1990;75:867-872.
51. Landers DV, Wølner-Hanssen P, Paavonen J, et al. Combination antimicrobial therapy in the treatment of acute pelvic inflammatory disease. Am J Obstet Gynecol. 1991;164:849-858.
52. Moller BR. The role of mycoplasmas in the upper genital tract of women. Sex Transm Dis. 1983;10(Suppl):281-284.
53. Block BS, Mercer LJ, Ismail MY, Moawad AH. Clostridium difficile-associated diarrhea follows perioperative prophylaxis with cefoxitin. Am J Obstet Gynecol. 1985;153:835-838.
54. Privitera G, Scarpellini P, Ortisi G, et al. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother. 1991;35:208-210.
55. Centers for Disease Control. Pelvic inflammatory disease: Guidelines for prevention and management. MMWR. 1991; 40(RR-5):1-25.
56. Arredondo JL, Díaz V, Gaitan H, et al. Oral clindamycin and ciprofloxacin vs oral doxycycline and intramuscular ceftriaxone in the outpatient treatment of mild to moderate pelvic inflammatory disease. J Infect Dis. In press.
57. Hasselquist MB, Hillier S. Susceptibility of upper-genital tract isolates from women with pelvic inflammatory disease to ampicillin, cefpodoxime, metronidazole, and doxycycline. Sex Transm Dis. 1991;18: 146-149.
58. Johnson SR, Petzold CR, Galask RP. Clindamycin levels in reproductive tissues. Am J Reprod Immunol. 1985;8:67-70.
59. Elder MG, Bywater MJ, Reeves D. Pelvic tissue and serum concentrations of various antibiotics given as pre-operative medication. Br J Obstet Gynaecol. 1977; 84:887-893.
60. Goormans E, Dalhoff A, Kazzas B. Penetration of ciprofloxacin into gynecological tissues following oral and intravenous administration. Chemotherapy. 1986;32: 7-17.
61. Wasserheit JN, Bell TA, Kiviat NB, et al. Microbial causes of proven pelvic inflammatory disease and efficacy of clindamycin and tobramycin. Ann Intern Med. 1986;104:187-193.
62. Wølner-Hanssen P, Paavonen J, Kiviat NB, et al. Outpatient treatment of pelvic inflammatory disease with cefoxitin and doxycycline. Obstet Gynecol. 1988;71: 595-600.
63. Hoegsberg B, Abulafia O, Sedlis A. Sexually transmitted diseases and human immunodeficiency virus among women with pelvic inflammatory disease. Am J Obstet Gynecol. 1990;163:1135-1139.
64. Stovall TG, Thorpe EM, Ling FW. Treatment of post-cesarean section endometritis with ampicillin and sulbactam or clindamycin and gentamicin. J Reprod Med. 1993;38:843-848.
65. Resnik E, Harger JH, Kuller JA. Early postpartum endometritis. Randomized comparison of ampicillin/sulbactam versus ampicillin, gentamicin and clindamycin. J Reprod Med. 1994;39:467-472.
66. McGregor JA, Crombleholme WR, Newton E, et al. Randomized comparison of ampicillin/sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometriosis. Obstet Gynecol. 1994;83:998-1004.
67. Dodson MG, Faro S, Gentry L. Treatment of acute pelvic inflammatory disease with aztreonam, a new monocyclic β-lactam antibiotic, and clindamycin. Obstet Gynecol. 1986;67:657-662.
68. Mangoni C, Bianchi L, Bolis PF, et al. Multicenter trial of prophylaxis with clindamycin plus aztreonam or cefotaxime in gynecologic surgery. Rev Infect Dis. 1991;13(Suppl 7):S621-S625.
69. Boeckh M, Lode H, Deppermann M, et al. Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole and ornidazole. Antimicrob Agents Chemother. 1990;34:2407-2414.
70. Krasemann C. Sensitivity of bacteroidaceae, peptococaceae, and clostridiae to ciprofloxacin with seven other antibiotics. Chemioterapia. 1985;2(Suppl 4):392-393.
71. Brook I. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: Correlation with in vitro susceptibilities. Antimicrob Agents Chemother. 1993;37:997-1000.
72. Pefanis A, Thauvin-Eliopoulos C, Holden J, et al. Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses. Antimicrob Agents Chemother. 1994;38:252-255.